Skip to main content

Table 4 Overview of literature

From: Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia

Author Stage Type of radiation treatment Total dose Treatment response PFS OS
Lindahl et al.[16] T1 5.7% TSEBT High-dose (30 Gy) n = 25 High-dose: CR 68% 9 months median n. a.
  T2 40%   Low-dose (4 Gy) n = 10 Low-dose:CR 10%   
  T3 48.6%      
  T4 5.7%      
Navi et al.[17] T2 57% TSEBT (+/- HN2) 36 Gy (range 30-40 Gy) T2: CCR 75% T2: 8.5 years T2: 10.9 years
  T3 43%    T3: CCR 47% T3: 2.9 years T3: 4.7 years
Kamstrup et al.[16] T2 n = 6 TSEBT 10 Gy OR 90% median response duration 5.2 months n. a.
  T3 n = 2    CR 30%   
  T4 n = 2      
Chinn et al.[18] T2 n = 55 TSEBT (+/- HN2) Mostly 36 Gy T2: CR 76% Freedom from recurrence at 1 year 41% T2: 10.7 years
  T3 n = 27    T3: CR 44%   T3: 3.6 years
This Analysis IIB n = 4 TSEBT Median 29 Gy OR 92% 5 months 10 months
  III n = 1    CCR 52%   
  IVA n = 10      
  IVB n = 7      
  1. Abbreviations: TSEBT total skin electron beam therapy, CR complete remission, CCR clinical complete remission, OR overall response, PFS progression free survival, OS overall survival.